Clinical features of patients with dSSc
| Patient | Age (years) | Sex | Duration of disease from the first non-Raynaud manifestation (years) | ANA | Raynaud | Oesophageal dysmotility | Tlco (%) | FVCL | Myocardiopathy | Pulmonary interstitial fibrosis | Skin score29 | Drug treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tlco %, carbon monoxide transfer factor (ml/mm Hg/min); FVCL, forced vital capacity-L; ANA, antinuclear antibodies; Neg, negative; NSAIDs, non-steroidal anti-inflammatory drugs. | ||||||||||||
| 1 | 50 | F | 4 | Neg | + | + | 32 | 1.52 | − | + | 32 | Nifedipine, Carboprostacyclin |
| 2 | 61 | F | 9 | Scl-70 | + | + | 83 | 2.37 | − | − | 19 | Nifedipine, NSAIDs |
| 3 | 57 | F | 10 | Neg | + | + | 55 | 2.4 | − | + | 15 | Captopril, Carboprostacyclin |
| 4 | 31 | F | 6 | Scl-70 | + | + | 95 | 2.91 | − | + | 16 | Carboprostacyclin |
| 5 | 52 | F | 4 | Scl-70 | + | + | 67 | 2.55 | − | − | 13 | Nifedipine |
| 6 | 73 | F | 2 | Neg | + | + | 58 | 2.81 | − | + | 13 | Enalapril |
| 7 | 43 | F | 7 | Neg | + | + | 47 | 2.02 | − | + | 40 | Carboprostacyclin, Nifedipine |
| 8 | 52 | F | 5 | Scl-70 | + | − | 87 | 3.57 | − | + | 14 | Enalapril |
| 9 | 35 | F | 6 | Anticentromere | + | + | 55 | 2.75 | − | + | 46 | Carboprostacyclin, Nifedipine |
| 10 | 66 | F | 10 | Neg | + | + | 67 | 1.81 | − | + | 22 | Nifedipine |
| Mean (SD) | 52 (13.1) | – | 6.3 (2.7) | − | − | 64.6 (19.3) | 2.47 (0.59) | − | − | 23 (12.06) | ||